The phase III candidate: Can we improve the science of selection?

Journal of Clinical Oncology

Volumn 22, Issue 2, 2004, Pages 211-213

  Bajorin, Dean ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; VINBLASTINE; ANTINEOPLASTIC AGENT;

BLADDER CANCER; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; CYSTECTOMY; DRUG EFFICACY; EDITORIAL; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; GIANT CELL TUMOR; HUMAN; MUCOSA INFLAMMATION; PATIENT CARE; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RESEARCH SUBJECT; TOXICITY; TREATMENT OUTCOME; DECISION MAKING; METHODOLOGY; NEOPLASM; ONCOLOGY; PATIENT CARE PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; DECISION MAKING; EVIDENCE-BASED MEDICINE; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PATIENT CARE PLANNING; RESEARCH DESIGN;

EID: 1342289780     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.988     Document Type: Editorial

References (11)

1. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-73, 1992
2. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003
3. Sternberg CN, de Mulder PHM, Schornagel JH, et al: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 19:2638-2646, 2001
4. Logothetis CJ, Dexeus F, Sella A, et al: A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
5. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized multicenter, multinational multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
6. Siefker-Radtke AO, Millikan RE, Tu S-M, et al: Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 20:1361-1367, 2002
7. Bamias A, Aravantinos G, Deliveliotis C, et al: Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22:10.1200/JCO.2004.02.152
8. Loehrer P, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study. J Clin Oncol 10:1066-1073, 1992
9. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome to chemotherapy. J Clin Oncol 17:3173-3181, 1999
10. Verbel DA, Kelly WK, Smaletz O, et al: Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to a definitive phase III trial. Urology 61:142-144, 2003
11. International Germ Cell Consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997